Alexion has made its name by developing Soliris (eculizumab), first launched in 2007, and is on track to earn $2.5 billion this year through treating two life-threatening and ultra-rare disorders ...

NICE and Alexion not backing down The Soliris appraisal has largely been conducted via complex health economic arguments and counter arguments, but NICE's HST committee and representatives came ...

The FDA first approved eculizumab for use in adult patients with generalized myasthenia gravis in 2017, before expanding the ...

approval of the expanded indication of Alexion/AstraZeneca’s eculizumab (Soliris) for pediatric patients aged six years and older with generalized myasthenia gravis (gMG) who are anti ...

Alexion, AstraZeneca Rare Disease has received ... treatment with C5 inhibitors such as Ultomiris (ravulizumab) or Soliris (eculizumab). The FDA’s decision is grounded in the positive outcomes ...

Alexion CEO Marc Dunoyer stated ... Ultomiris was benchmarked against an external placebo group from the Soliris PREVENT clinical trial. The primary endpoint of time to first on-trial relapse ...

Significant case: Michael Canty secured a $125 million settlement against Alexion Pharmaceuticals, exposing illegal sales tactics for their blood disorder drug Soliris. He also achieved a $90 ...

While Alexion continues to be viewed as the most respected industry ... positioning it as a likely disruptor to Ultomiris and Soliris upon its introduction. This latest research underscores Spherix’s ...

2 While complement 5 (C5) inhibitors such as Soliris and Ultomiris have long ... alongside newer market entrants Voydeya (Alexion/AZ) and PiaSky (Genentech/Roche), offering new mechanisms for ...